What Happened

Takeda Pharmaceutical announced layoffs of 247 Massachusetts employees starting July 2026 as part of its Transformation Program, a restructuring effort approved in March 2026. The program aims to save $1.2 billion annually by 2028, driven by the collapse of VYVANSE, its blockbuster ADHD drug, which lost U.S. patent protection in 2023.

Who Is Affected

The layoffs impact 247 Massachusetts employees, with some cuts extending into 2027. A Takeda spokesperson confirmed these layoffs are part of a global reduction of 4,500 jobs by March 2027. Most affected employees have already found other roles within the company, which has 2,100 open positions globally.

Market Impact

• Takeda’s restructuring reflects the financial impact of VYVANSE’s patent loss, with domestic sales dropping 63% last fiscal year.
• The company is betting on three experimental drugs—oveporexton, rusfertide, and zasocitinib—to replace lost revenue.
• FDA decisions on oveporexton and rusfertide are expected as soon as August 2026.

What to Watch

Monitor Takeda’s pipeline launches and FDA rulings on its experimental drugs, which could signal new revenue streams. Additionally, track the company’s internal hiring priorities and restructuring progress for potential opportunities.